- Switching HIV-infected patients on mono or dual therapy (plus lamivudine [3TC]) from a darunavir/ritonavir (DRV/r)- to darunavir/cobicistat (DRV/c)-based regimen maintains viral suppression (VS).
Why this matters
- A DRV/c mono- or dual-based therapy plus 3TC is an effective, simplified switch regimen for virally suppressed, HIV-infected patients and may help boost adherence, convenience.
- DRV/c is not recommended for patients with cobicistat intolerance, or in pregnant women.
- 162 patients.
- Intent-to-treat efficacy, on-treatment efficacy at week 48 were 95.1% (95% CI, 90.65%-97.5%), 98.7% (95% CI, 95.5%-99.6%), respectively.
- 8 DRV/c-based mono or dual therapy discontinuations, 2 viral failures:
- Patient 1: HIV-RNA was 10,600 copies/mL at week 24; patient withdrew, restarted DRV/c mono therapy plus 2 nucleoside reverse transcriptase inhibitors (NRTIs).
- Patient 2: HIV-RNA load of 320 copies/mL at week 12 detectable 10 days later (198 copies/mL); 2 NRTIs introduced with undetectable viral load.
- No severe clinical/laboratory adverse events (AEs) observed.
- Observational, prospective, multicenter cohort evaluating efficacy of switching DRV/r-based mono or dual (plus 3TC) to a DRV/c-based therapy while maintaining the previous regimen in HIV-infected patients.
- Funding: Fondo de Investigación Sanitaria, Fundación Profesor Novoa Santos, A. Carûna.
- Underpowered to detect uncommon AEs.
- No pharmacokinetic data.